TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
Life Sciences & Drug Development · Next decade may see ChatGPT-style breakthroughs in biology where venture investing has historically struggled
now playing · Life Sciences & Drug Development
AI Infrastructuretailwindscore 8/10nico laqua
Enterprise AI workloads shifting to Anthropic over OpenAI on product superiority
Corgi CEO reports Anthropic's Claude outperforms OpenAI for enterprise workflow automation, driving $400k/month spend with zero OpenAI usage, suggesting a potential shift in enterprise AI i…
Life Sciences & Drug Developmenttailwindscore 7/10nico laqua
Next decade may see ChatGPT-style breakthroughs in biology where venture investing has historically struggled
Nico Laqua identifies biology as sector where venture hasn't worked well previously but could see category-defining outcomes as smart talent enters, predicting more 'ChatGPT moments' in com…
Venture Capitaltailwindscore 6/10nico laqua
VCs should align deployed capital with desired ecosystem changes rather than passive investing
Nico Laqua argues venture funds are in strong position to shape startup ecosystem through incentive alignment, and should take active stances aligning capital with worldview rather than rel…